S
Sydnexis
About Sydnexis
Sydnexis is a healthcare startup that operates in the pharmaceutical industry, specifically focusing on the treatment of myopia in children. Myopia, also known as nearsightedness, is a common eye condition that causes distant objects to appear blurry. Sydnexis has developed a patented formulation that is designed for comfort and efficacy, aiming to halt the progression of myopia in children.
Read full description
The company's business model revolves around the development, production, and commercialization of this unique formula. They generate revenue by selling their product to healthcare providers who then prescribe it to patients. The company is currently in the Phase 3 study of their product, which is the final phase before the product can be approved for public use.
Sydnexis recently appointed Nick Ruth as its Chief Commercial Officer, signaling their readiness to commercialize their product. The company has also been featured in the Review of Myopia Management, where the founders discussed the uniqueness of their formula and its benefits for juvenile-onset myopic children.
The company's target market is primarily healthcare providers who treat myopia in children. However, given the prevalence of myopia, the potential market for their product is vast.
In summary, Sydnexis is a pharmaceutical startup that has developed a unique, patented formula for the treatment of myopia in children. They generate revenue by selling their product to healthcare providers.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Del Mar, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 34.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2021 | $45M | $180M | Bluestem Capital · Visionary Ventures · Longitude Capital · RA Capital Management | — |
| EARLY VCOther financing | Oct 2017 | $5.5M | $22M | Medicxi · RA Capital Management | — |
Growth signals
Latest recorded traffic for Sydnexis is 740 monthly website visits, down 82% over the last three months. Sydnexis's team declined 21.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Medicxi
RA Capital Management
Bluestem Capital- VVVisionary Ventures
SC Master Fund
Longitude Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sydnexis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sydnexis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.